[go: up one dir, main page]

WO2021003321A1 - Procédés de traitement de vides tissulaires après élimination de ports de perfusion implantables à l'aide de produits de tissus adipeux - Google Patents

Procédés de traitement de vides tissulaires après élimination de ports de perfusion implantables à l'aide de produits de tissus adipeux Download PDF

Info

Publication number
WO2021003321A1
WO2021003321A1 PCT/US2020/040582 US2020040582W WO2021003321A1 WO 2021003321 A1 WO2021003321 A1 WO 2021003321A1 US 2020040582 W US2020040582 W US 2020040582W WO 2021003321 A1 WO2021003321 A1 WO 2021003321A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
adipose
matrix
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/040582
Other languages
English (en)
Inventor
Hui Xu
Carrie Fang
Mrinal Shah
Israel James Jessop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeCell Corp
Original Assignee
LifeCell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/502,640 external-priority patent/US11123375B2/en
Application filed by LifeCell Corp filed Critical LifeCell Corp
Publication of WO2021003321A1 publication Critical patent/WO2021003321A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present disclosure relates generally to methods to prevent complications arising from removal of objects or tissue from soft tissues.
  • the disclosures herein relate to methods of preventing complications arising from removal of implantable infusion ports or other implantable devices from a soft tissue.
  • the methods can include use of a flowable adipose-derived acellular tissue matrix composition.
  • Seromas usually resolve spontaneously over six-to-eight weeks without treatment. Uncommonly a seroma may become large and/or infected and require aspiration or open (surgical) drainage.
  • the seroma is experienced by the patient as a hard, tender subcutaneous“lump.”
  • the lump is a source of concern and anxiety for the patient— particularly, the cancer patient.
  • healing may leave a firm or hard subcutaneous scar that may take years to resolve.
  • the overlying skin is pulled downward to create a pronounced concavity in the skin, leaving a noticeable deformity.
  • the present disclosure also provides methods of using
  • compositions comprising an acellular adipose tissue matrix to eliminate a dead space at the time of or after removal of a soft tissue mass.
  • the steps include removing an implanted infusion port form an anatomic location of a subject to create a void; and delivering a flowable composition comprising an adipose-based tissue matrix into the void at t time proximate to the removing step.
  • the composition is delivered into the soft tissue defect at a time proximate to the removing step.
  • compositions comprising a flowable adipose acellular tissue matrix are described, and such compositions are suitable for small-volume treatment or injection.
  • the compositions and methods described herein allow for filling of a soft tissue defect, wherein the subcutaneous dead space is filled with a volume flowable acellular adipose tissue matrix and the skin incision is closed, whereby the flowable acellular adipose tissue matrix is contained within the soft tissue dead space.
  • the recipient subject s own adipocytes and other cells including vascular endothelial cells, periadipocytes, and fibroblasts colonize the flowable acellular adipose tissue matrix to form new adipose tissue.
  • These cells produce collagen, glycoproteins, and other components as the flowable acellular adipose tissue matrix is re-modeled and fully incorporated into the recipient subject’s own adipose tissue.
  • the present disclosure provides methods for repairing a skin deformity comprising making a skin incision proximate to a deformity; dividing subcutaneous scar tissue to release skin attached to the scar tissue, creating a dead space; injecting a flowable composition containing an adipose-based tissue matrix into the dead space; and closing the skin incision.
  • the present disclosure also provides compositions for injection, small-volume implantation, or filling of larger voids or adding volume with adipose- based tissue products.
  • the disclosure also provides methods for producing such compositions.
  • the present disclosure provides methods for producing an injectable product from adipose tissue matrix.
  • the method may include selecting an adipose tissue; mechanically processing the adipose tissue to reduce the tissue size; treating the mechanically processed tissue to remove substantially all cellular material from the tissue; suspending the tissue in a solution to form a suspension; treating the suspension to produce a stabilized three-dimensional structure with a micro-porous structure; and mechanically processing the stabilized three- dimensional structure to produce particles.
  • the present disclosure also provides tissue product compositions.
  • compositions may include a particulate tissue matrix, wherein the tissue product composition comprises an adipose acellular tissue matrix that has been formed into a porous sponge and then formed into the particulate, and wherein the particulate tissue matrix comprises particles having a longest dimension between about 0.05 mm and 3 mm.
  • FIG. 1 is a flow chart outlining a process for producing an adipose tissue matrix sponge, according to embodiments of the present disclosure
  • FIG. 2 is a flow chart outlining a process for producing an injectable adipose tissue matrix product, according to embodiments of the present disclosure
  • FIG. 3 illustrates a bulk piece of adipose tissue matrix sponge produced according to various embodiments
  • FIG. 4 is an enlarged view of a particulate tissue matrix having dimensions between 2 and 3 mm after being produced by milling an adipose tissue matrix sponge;
  • FIG. 5 illustrates a group of acellular tissue matrix particulates produced by milling or fracturing an adipose tissue matrix sponge to produce particles between 100 and 300 microns (pm), and a paste/pudding-like injectable material after its hydration;
  • FIG. 6 illustrates scanning electron microscopy (SEM) and atomic force microscopy photos of adipose tissue matrix particles produced according to the process of the disclosed Examples;
  • FIG. 7 A illustrates differential scanning calorimetry curves for adipose tissue matrix material produced according to the disclosed Examples
  • FIG. 7B is a Mason’s trichrome stained section of adipose tissue matrix material produced according to the disclosed Examples;
  • FIG. 7C illustrates collagenase digestion curves for adipose tissue produced according to the disclosed Examples, with or without e-beam sterilization;
  • FIG. 8A is a hematoxylin and eosin (‘ ⁇ &E”) stained section of adipose tissue matrix material produced according to the disclosed Examples;
  • FIG. 8B is a table of DNA and lipid content measurement for adipose tissue produced according to the disclosed Examples
  • FIG. 8C is an immune-stained portion of adipose tissue matrix material, negative for MFIC-1 & II staining as compared to a native fat control, produced according to the disclosed Examples;
  • FIG. 9 provides histologic images of adipose tissue matrix produced according to the disclosed Examples as compared to native fat controls and subject to an immune-histological analysis for major extracellular matrix proteins (e.g., Type I, Type III, and Type IV) collagens;
  • major extracellular matrix proteins e.g., Type I, Type III, and Type IV
  • FIG. 10 provides light microscopic images of adipose tissue matrix produced according to the disclosed Examples supporting growth of three different cell types in vitro (e.g., adipogenic mesenchymal stem cells, endothelial cells, and dermal fibroblasts);
  • FIG. 11 provides gross photographs of explants of injectable adipose tissue matrix after subcutaneous implant in nude rats as prepared according to the enclosed Examples;
  • FIG. 12 illustrates Masson’s Trichrome staining of the explants of injectable adipose tissue matrix after subcutaneous implant in nude rats as prepared according to the enclosed Examples;
  • FIG. 13 is a bar graph illustrating explant volume remaining after rat subcutaneous implant for four or eight weeks, as described in the enclosed
  • FIG. 14A is a Masson Trichrome stained section of eight week explants as described in the enclosed Examples;
  • FIG. 14B is another Masson Trichrome stained section of eight week explants as described in the enclosed Examples.
  • FIG. 14C is another Masson Trichrome stained section of eight week explants as described in the enclosed Examples.
  • FIG 15 provides microscopic images of aggregates formed in a wet adipose tissue matrix product after 1.5 years of storage
  • FIG 16 is a graph of injection force for adipose matrix products with or without FIA as a flowable carrier
  • FIG 17 is an H&E stained section of a four-week FIA-adipose explant as described in the Examples;
  • FIG. 18 is a flowchart outlining a process for creating and repairing a soft tissue void using a flowable adipose-based tissue matrix, according to embodiments of the present disclosure
  • FIG. 19 is a flowchart outlining a process for repairing a skin deformity using a flowable adipose-based tissue matrix, according to embodiments of the present disclosure
  • FIG. 20 is a graph illustrating volume retention of an adipose matrix composition implanted subcutaneously for up to twelve weeks, according to the disclosed Examples;
  • FIGs. 21 A-D illustrates gross images of an acute wound model with or without implantation of an adipose tissue matrix composition
  • FIGs. 22A-D illustrates gross images of a chronic wound model with or without implantation of an adipose tissue matrix composition.
  • tissue product will refer to any human or animal tissue that contains an extracellular matrix protein.
  • tissue products may include acellular or partially decellularized tissue matrices, as well as decellularized tissue matrices that have been repopulated with exogenous cells.
  • acellular tissue matrix refers to an extracellular matrix derived from human or animal tissue, wherein the matrix retains a substantial amount of natural collagen and glycoproteins needed to serve as a scaffold to support tissue regeneration.
  • Acellular tissue matrices are different from the purified collagen materials, such as acid-extracted purified collagen, which are substantially void of other matrix proteins and do not retain the natural micro- structural features of tissue matrix due to the purification processes.
  • tissue matrices may be combined with exogenous cells, including, for example, stem cells, or cells from a patient in whom the“acellular tissue matrices” may be implanted.
  • a “decellularized adipose tissue matrix” will be understood to refer to an adipose-based tissue from which all cells have been removed to produce adipose extracellular matrix. “Decellularized adipose tissue matrix” can include intact matrix or matrix that has been further processed as discussed herein, including mechanical processing, formation of a sponge, and/or further processing to produce particulate matrix.
  • tissue matrices will be understood to refer to tissue matrices in which no cells are visible using light microscopy.
  • Adipose tissue relates to any number of fat- containing tissues, including subcutaneous fat, fat pads, breast tissue, and the like. [0053] Removal of a mass from soft tissue creates a dead space, as discussed. For example, removal of an implantable tissue port from the
  • subcutaneous tissue of the chest wall creates a dead space that often leads to seroma formation, which the patient may experience as a painful, anxiety-provoking lump.
  • removal of the implantable port can create a volume defect in the subcutaneous fat that is manifest as a depression deformity in the overlying skin.
  • Various human and animal tissues may be used to produce products for a dead space to prevent complications and skin deformity following removal of a mass from soft tissue.
  • various tissue products for regeneration, repair, augmentation, reinforcement, and/or treatment of human tissues that have been damaged or lost due to various diseases and/or structural damage e.g., from trauma, surgery, atrophy, and/or long-term wear and
  • Such products may include, for example, acellular tissue matrices, tissue allografts or xenografts, and/or reconstituted tissues (i.e. , at least partially decellularized tissues that have been seeded with cells to produce viable materials).
  • ALLODERM® and STRATTICETM are two dermal acellular tissue matrices made from human and porcine dermis, respectively. Although such materials are very useful for treating certain types of conditions, materials having different biological and mechanical properties may be desirable for certain applications.
  • ALLODERM® and STRATTICETM have been used to assist in the treatment of structural defects and/or to provide support to tissues (e.g., for abdominal walls or in breast reconstruction), and their strength and biological properties make them well suited for such uses.
  • tissue products that are useful for the treatment of a tissue defects/imperfections involving adipose- containing tissues, such as a dead space in the subcutaneous fat following removal of an implantable injection port.
  • the present disclosure also provides methods for producing these tissue products.
  • the tissue products may include adipose tissues that have been processed to remove at least some of the cellular components. In some cases, all, or substantially all cellular materials are removed, thereby leaving adipose extracellular matrix proteins. In addition, the products may be processed to remove some or all of the extracellular and/or intracellular lipids. In some cases, however, complete removal of extracellular and/or intracellular lipids can be damaging to the architecture and functions of the adipose matrix. For example, adipose tissues that are chemically or enzymatically treated for an extended period of time may have denatured or otherwise damaged collagen, or may be depleted of proteins needed for adipose regeneration.
  • the product contains a certain level of residual lipids.
  • the remaining lipid content can be, for example, about 5%, 6%, 7%, 8%, 9%, or 10% by weight of the product.
  • the extracellular matrix proteins may be further treated to produce a three-dimensional porous, or sponge-like material, and the porous or sponge-like material may be further processed to produce an injectable product.
  • the tissue products of the present disclosure are formed from adipose tissues.
  • the adipose tissues may be derived from human or animal sources.
  • human adipose tissue may be obtained from cadavers.
  • human adipose tissue could be obtained from live donors (e.g., with autologous tissue).
  • Adipose tissue may also be obtained from animals such as pigs, monkeys, or other sources. If animal sources are used, the tissues may be further treated to remove antigenic components such as 1 ,3-alpha-galactose moieties, which are present in pigs and other mammals, but not humans or primates.
  • antigenic components such as 1 ,3-alpha-galactose moieties, which are present in pigs and other mammals, but not humans or primates.
  • Hui, et al. “A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-a-(1 ,3)-Galactose and Retention of Matrix Structure,” Tissue Engineering, Vol. 15, 1 -13 (2009), which is hereby incorporated by reference in its entirety.
  • the adipose tissue may be obtained from
  • FIG. 1 provides a flow chart illustrating the basic steps that may be used to produce a suitable adipose tissue sponge, which can then be further processed to produce injectable or implantable particulate. As shown, the process may include a number of steps, but it will be understood that additional or alternative steps may be added or substituted depending on the particular tissue being used, desired application, or other factors.
  • the process 100 may begin generally at Step 110, wherein tissue is received.
  • the tissue may include a variety of adipose tissue types, including, for example, human or animal adipose tissue.
  • Suitable tissue sources may include allograft, autograft, or xenograft tissues.
  • the tissue may include adipose from animals including porcine, cow, dog, cat, domestic or wild sources, and/or any other suitable mammalian or non-mammalian adipose source.
  • the tissue may be harvested from animal sources using any desirable technique, but may be generally obtained using, if possible, aseptic or sterile techniques.
  • the tissue may be stored in cold or frozen conditions or may be immediately processed to prevent any undesirable changes due to prolonged storage.
  • the tissue may initially be subject to mechanical size reduction at Step 120 and/or mechanical defatting at Step 130.
  • Mechanical size reduction may include gross or large cutting of tissue using manual blades or any other suitable grinding process.
  • Mechanical defatting at Step 130 may be important in the production of tissue.
  • the adipose may be subject to a variety of mechanical processing conditions.
  • the mechanical processing may include grinding, blending, chopping, grating, or otherwise processing the tissue.
  • the mechanical processing may be performed under conditions that allow for a certain degree of heating, which may assist in liberating or removing lipids.
  • the mechanical processing may be performed under conditions that may allow the adipose tissue to heat up to 122°F (50°C).
  • the application of external heat may be insufficient to release the lipids; therefore, heat generated during mechanical disruption may be preferred to assist in lipid removal.
  • heating during mechanical processing may be a pulse in temperature rise and may be short in duration. This heat pulse may cause liquefaction of lipid released from broken fat cells by mechanical disruption, which may then cause efficient phase separation for bulk lipid removal.
  • the temperature reached during this process is above 100°F and may not exceed 122°F (50°C). The range of
  • the temperature reached can be adjusted according to the origin of the adipose tissue. For example, the temperature can be further lowered to about 80°F, 90°F, 100°F,
  • the process may be selected to ensure the adipose reaches a minimum temperature such as 80°F, 90°F, 100°F, 110°F, or 120°F.
  • the mechanical defatting may be performed by mechanically processing the tissue with the addition of little or no washing fluids.
  • the tissue may be mechanically processed by grinding or blending without the use of solvents.
  • water may be used, including pure water or saline or other buffers including saline or phosphate buffered saline.
  • the tissue may be processed by adding a certain quantity of solvent that is biocompatible, such as saline (e.g., normal saline, phosphate buffered saline, or solutions including salts and/or detergents).
  • saline e.g., normal saline, phosphate buffered saline, or solutions including salts and/or detergents.
  • Other solutions that facilitate cell lysis may also be appropriate, including salts and/or detergents.
  • the adipose may be washed at Step 140.
  • the tissue may be washed with one or more rinses with various biocompatible buffers.
  • suitable wash solutions may include saline, phosphate buffered saline, or other suitable biocompatible materials or physiological solutions.
  • water may be used as a rinsing agent to further break the cells, after which phosphate buffered saline, or any other suitable saline solution, may be introduced to allow the matrix proteins to return to biocompatible buffers.
  • the washing may be performed along with centrifugation or other processes to separate lipids from the tissue.
  • the material is diluted with water or another solvent.
  • the diluted material is then centrifuged, and free lipids will flow to the top, while the extracellular matrix proteins are deposited as a pellet.
  • the protein pellet may then be resuspended, and the washing and centrifugation may be repeated until a sufficient amount of the lipids are removed.
  • the adipose may be treated to remove some or all cells from the adipose tissue as indicated at Step 150.
  • the cell removal process may include a number of suitable processes.
  • suitable methods for removing cells from the adipose tissue may include treatment with detergents such as deoxycholic acid, polyethylene glycols, or other detergents at concentrations and times sufficient to disrupt cells and/or remove cellular components.
  • additional processing and/or washing steps may be incorporated, depending on the tissue used or ultimate structure desired, as indicated at Step 160.
  • additional washing or treatment may be performed to remove antigenic materials such as alpha-1 ,3-galactose moieties, which may be present on non-primate animal tissues.
  • additional solutions or reagents may be used to process the material.
  • enzymes, detergents, and/or other agents may be used in one or more steps to further remove cellular materials or lipids, remove antigenic materials, and/or reduce the bacteria or other bioburden of the material.
  • one or more washing steps may be included using detergents, such as sodium dodecylsulfate or Triton to assist in cell and lipid removal.
  • detergents such as sodium dodecylsulfate or Triton to assist in cell and lipid removal.
  • enzymes such as lipases, DNAses, RNAses, alpha-galactosidase, or other enzymes may be used to ensure destruction of nuclear materials, antigens from xenogenic sources, residual cellular components and/or viruses.
  • acidic solutions and/or peroxides may be used to help further remove cellular materials and destroy bacteria and/or viruses, or other potentially infectious agents.
  • the material may then be formed into a porous or sponge-like material.
  • the extracellular matrix is first resuspended in an aqueous solvent to form a slurry-like material as indicated at Step 170.
  • a sufficient amount of solvent is used to allow the material to form a liquid mass that may be poured into a mold having the size and shape of the desired tissue product.
  • the amount of water or solvent added may be varied based on the desired porosity of the final material.
  • the slurry-like material may have a solid concentration of about 2% to about 10% by weight, preferably about 2% to about 5%.
  • the resuspended extracellular matrix may be mechanically treated by grinding, cutting, blending or other processes one or more additional times, and the treated material may be centrifuged and resuspended one or more times to further remove cellular material or lipids (if needed) and/or to control the viscosity of the extracellular matrix.
  • the resuspended material is placed in a container or mold to form the porous, sponge like product, as indicated at Step 180.
  • the porous or sponge-like material is formed by drying the material to leave a three-dimensional matrix with a porous structure.
  • the material is freeze-dried. Freeze-drying may allow production of a three-dimensional structure that generally conforms to the shape of the mold, as shown in FIG. 3.
  • the specific freeze drying protocol may be varied based on the solvent used, sample size, and/or to optimize processing time.
  • One suitable freeze-drying process may include cooling the material to -10°C over a 20-40 minute period; holding the samples at -10°C for 120-180 minutes and further cooling the sample to -40°C to insure complete freezing; applying a vacuum; raising the temperature to -5°C and holding for 30-60 hours; raising the temperature to 25°C and holding for 6-12 hours.
  • the freeze-dried samples may then be removed from the freeze-dryer and packaged in foil pouches under nitrogen.
  • the material may optionally be stabilized, as indicated at Step 190.
  • the stabilization may include additional processes such as cross-linking, treatment with dehydrothermal (DHT) processes, or other suitable stabilization methods.
  • DHT dehydrothermal
  • a mechanically processed tissue when formed into a porous matrix, may form a more putty- or paste-like material when it is implanted in a body, becomes wet, or is placed in a solution. Therefore, the desired shape and size may be lost.
  • the porous structure which may be important for supporting cell attachment, tissue growth, vascular formation, and tissue regeneration, may be lost. Accordingly, the material may be further processed to stabilize the size, shape, and structure of the material.
  • the material is cross-linked for stabilization.
  • the material is cross-linked after freeze drying. Flowever, the material could also be cross-linked before or during the freeze-drying process.
  • Cross-linking may be performed in a variety of ways.
  • cross- linking is accomplished by contacting the material with a cross-linking agent such as glutaraldehyde, genepin, carbodiimides (e.g., 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)), and diisocyantes.
  • a cross-linking agent such as glutaraldehyde, genepin, carbodiimides (e.g., 1 -ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)), and diisocyantes.
  • EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
  • diisocyantes e.g., 1, 2-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (
  • the material may be heated to between 70°C to 120°C, or between 80°C and 110°C, or to about 100°C, or any values between the specified ranges in a reduced pressure or vacuum.
  • other cross-linking processes, or combination of processes may be used to produce any of the disclosed products, including ultraviolet irradiation, gamma irradiation, and/or electron beam irradiation.
  • a vacuum is not needed but may reduce cross-linking time. Further, lower or higher temperatures could be used as long as melting of the matrix proteins does not occur and/or sufficient time is provided for cross-linking.
  • the cross-linking process may be controlled to produce a tissue product with desired mechanical, biological, and/or structural features.
  • cross-linking may influence the overall strength of the material, and the process may be controlled to produce a desired strength.
  • the amount of cross-linking may affect the ability of the product to maintain a desired shape and structure (e.g., porosity) when implanted. Accordingly, the amount of cross-linking may be selected to produce a stable three-dimensional shape when implanted in a body, when contacted with an aqueous environment, and/or when compressed (e.g., by surrounding tissues or materials).
  • Excessive cross-linking may change the extracellular matrix materials. For example, excessive cross-linking may damage collagen or other extracellular matrix proteins. The damaged proteins may not support tissue regeneration when the tissue products are placed in an adipose tissue site or other anatomic location. In addition, excessive cross-linking may cause the material to be brittle or weak. Accordingly, the amount of cross-linking may be controlled to produce a desired level of stability, while maintaining desired biological, mechanical, and/or structural features.
  • Exemplary cross-linking processes may include contacting a freeze- dried material, produced as discussed above, with glutaraldehyde or EDC.
  • glutaraldehyde or EDC For example, a 0.1 % glutaraldehyde solution may be used, and the tissue may be submerged in the solution for about for 18 hours followed by extensive rinsing in water to remove the solution.
  • a dehydrothermal (DHT) process may be used.
  • one exemplary dehydrothermal process includes treating the material at 100°C and ⁇ 20 inches of Fig for 18 hours, followed by submersion in water.
  • the final cross-linked tissue products may be stored in a film pouch.
  • the tissue product may then be further processed to produce an injectable form.
  • An exemplary process for forming an injectable form is illustrated by Process 200, as shown in FIG. 2.
  • “injectable” may include materials injected with a syringe, cannula, or needle, but the disclosed material can be produced having sizes and mechanical properties suitable for other modes of administration, including manual insertion (e.g., with a hand or other bulk instrument such as a spatula, tube, or other device equipped to handle flowable materials).
  • the process for producing the injectable begins by obtaining the bulk sponge, as indicated at Step 210.
  • Obtaining the bulk sponge may be performed using the process described with reference to FIG. 1 , or suitable variations thereof.
  • the process may start with stable (porcine or human) adipose tissue matrix sponges.
  • the material may be subject to size reduction or particulate formation, as indicated at Step 220.
  • the size reduction or particulate formation may include mechanical cutting, grinding, or blending to produce particulates of a desired size and size distribution.
  • grinding may be preferred to reduce the dry sponge to smaller particles. Size reduction may be performed at room temperature.
  • the particles should be large enough to maintain the sponge structure in order to support adipogenesis. Loss or lack of the porous structure can result in a composition that does not support adipose growth.
  • the particles may be formed from a sponge such that the particles have a size of at least 0.5 microns,
  • the particle size may be selected based on the sponge microstructure.
  • a size selection may be desired.
  • a stabilized sponge once ground or otherwise treated to produce particles, may then be sieved or otherwise sorted to obtain a desired size of particles as flowable/injectable adipose tissue matrix material.
  • one or more injectable adipose tissue matrix sponges with distinct particle sizes may be desired to accommodate different needle sizes.
  • the material is sieved to achieve preferred particle size ranges.
  • particle sizes may range from 50 microns to 2,800 microns.
  • the ground sponge may be sieved to retrieve particles with the following preferred dimensions: Fine particles (e.g., 50-100 microns); Medium particles (e.g., 0.4 mm to 0.6 mm); Large particles (e.g., 0.8 mm to 1 mm); and Larger particles (e.g., 2.8 mm to 3.4 mm).
  • particle sizes in this range may not invoke a varied biological response. In other words, for example, there may be no difference in biological responses with particle sizes ranging from 50 microns to 3,400 microns. Different applications that may require a specific size of an injection needle may select a specific size of particle(s) without the need to consider if the biological responses will be different. Furthermore, in some cases, larger particles are used to increase volume retention, whereas smaller particles may be used when a smaller injection device is desired.
  • the particles may be hydrated and/or added to another carrier to a desired degree to produce flowability and desired degree of solid content.
  • the sieved particles may be hydrated with saline or other material(s) to result in a solid concentration of 5-12%.
  • other carriers may be used or added, including hyaluronic-acid based materials (e.g., JUVEDERM®, ALLERGAN, or similar materials).
  • the particles may be hydrated using water, saline, phosphate buffered saline, or any other suitable physiological solution.
  • Step 240 may be performed before Step 230, in that, the particles may be hydrated or added to a carrier before a size selection is made and/or before the particles are sieved.
  • FIGs. 4 and 5 Exemplary particulate materials are illustrated in FIGs. 4 and 5.
  • FIG. 4 is an enlarged view of a particulate tissue matrix having dimensions between 2 and 3 mm after being produced by milling an adipose tissue matrix sponge
  • FIG. 5 illustrates a group of acellular tissue matrix particulates produced by milling or fracturing an adipose tissue matrix sponge to produce particles between 100 and 300 microns, and a paste/pudding-like injectable material after its hydration;
  • a material with a desired tissue matrix solid content may be used.
  • a material that is 5% to 12% solid may be used, and a material that is 7.5-10% is desired.
  • a material that is 5% to 10% solid may use a suitable carrier to facilitate injection and to prevent particle dissipation away from the injection site.
  • the suitable carrier can be a flowable carrier, e.g. a flowable hyaluronic acid carrier.
  • the hyaluronic acid carrier is a non-crossl inked hyaluronic acid carrier.
  • the hyaluronic acid carrier is a cross-linked hyaluronic acid carrier.
  • a“hyaluronic acid based material” is a material comprising hyaluronic acid (HA).
  • HA refers to hyaluronic acid and can also refer to any salts thereof, including, but not limited to, sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, and combinations thereof. Both HA and pharmaceutically acceptable salts thereof can be included in the hyaluronic acid based material.
  • Exemplary HA based materials are commercially sold as JUVEDERM ® and JUVEDERM VOLUMA ®. It should be appreciated that the hyaluronic acid based material may include additional agents such as, for example, lidocaine.
  • the intrinsic viscosity is measured according to the procedure defined European Pharmacopoeia (HA monograph N°1472, 01/2009).
  • High molecular weight HA as used herein describes a HA material having a molecular weight of at least about 1.0 million Daltons (Mw > 10 6 Da or 1 MDa) to about 4.0 MDa.
  • High molecular weight HA that may be incorporated in the present tissue product compositions may have a molecular weight in the range about 1.5 MDa to about 3.0 MDa, or the high molecular weight HA may have a weight average molecular weight of about 2.0 MDa. In another example, the high molecular weight HA may have a molecular weight of about 3.0 MDa.
  • Low molecular weight HA as used herein describes a HA material having a molecular weight of less than about 1.0 MDa.
  • Low molecular weight HA can have a molecular weight of between about 200,000 Da (0.2 MDa) to less than 1.0 MDa, for example, between about 300,000 Da (0.3 M Da) to about 750,000 Da. (0.75 MDa), up to but not exceeding 0.99 MDa.
  • the mixture of the low molecular weight HA and high molecular weight HA has a bimodal molecular weight distribution. The mixture may also have a multi-modal distribution.
  • the adipose tissue product compositions comprise HA having a high molecular weight component and a low molecular weight component, and the high molecular weight component may have a weight average molecular weight at least twice the weight average molecular weight of the low molecular weight component.
  • the molecular weight ratio of the high molecular weight HA to the low molecular weight HA in the composition may be at least 2:1.
  • a tissue product composition may include an HA having a low molecular weight component having a weight average molecular weight of about 500,000 Da, and a high molecular weight component having a weight average molecular weight of about, or at least about, 1.0 MDa.
  • a tissue product composition in accordance with the invention may include an HA having a low molecular weight component having a weight average molecular weight of about 800,000 Da, and a high molecular weight component having a weight average molecular weight of about, or at least about, 1.6 MDa. It should be appreciated that many different types of HA may be incorporated in the adipose tissue product composition, and the foregoing examples are not intended to be limiting.
  • the HA may be cross-linked using one or more suitable crosslinking agents.
  • the crosslinking agent may be any agent known to be suitable for crosslinking polysaccharides and their derivatives via their hydroxyl groups.
  • Suitable crosslinking agents include but are not limited to, 1 ,4- butanediol diglycidyl ether (or 1 ,4-bis(2,3-epoxypropoxy)butane or 1 ,4- bisglycidyloxybutane, all of which are commonly known as BDDE), 1 ,2-bis(2,3- epoxypropoxy)ethylene, 1 -(2, 3-epoxypropyl)-2, 3-epoxycyclohexane, and 1 -ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (commonly known as EDC).
  • hyaluronan crosslinking agents include multifunctional PEG-based crosslinking agents like pentaerythritol tetraglycidyl ether (PETGE), divinyl sulfone (DVS), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EGDGE), 1 ,2,7,8-diepoxyoctane (DEO), (phenylenebis-(ethyl)-carbodiimide and 1 ,6 hexamethylenebis (ethylcarbodiimide), adipic dihydrazide (ADH), bis(sulfosuccinimidyl)suberate (BS),
  • PEG-based crosslinking agents like pentaerythritol tetraglycidyl ether (PETGE), divinyl sulfone (DVS), 1 ,2-bis(2,3-epoxypropoxy)ethylene (EGDGE), 1 ,2,7,8-diepoxyoc
  • the adipose tissue product composition includes a flowable carrier comprising a hyaluronic acid based material and a plurality of adipose tissue matrix particles mixed with the carrier.
  • the flowable carrier comprises HA that has not been mixed with additional agents; in other exemplary embodiments, the flowable carrier comprises HA mixed with additional agents.
  • Additional agents may include, but are not limited to, anesthetic agents for example, aminoamide local anesthetic and salts thereof or an aminoester local anesthetic and salts thereof.
  • anesthetic agents for example, aminoamide local anesthetic and salts thereof or an aminoester local anesthetic and salts thereof.
  • procaine chloroprocaine, cocaine, cyclomethycaine, cimethocaine, propoxycaine, procaine, proparacaine, tetracaine, or salts thereof, or any combination thereof.
  • anesthetic agents may comprise articaine, bupivacaine, cinchocaine, etidocaine, levobupivacaine, lidocaine, mepivacaine, piperocaine, prilocaine, ropivacaine, trimecaine, or salts thereof, or any combination thereof.
  • the flowable carrier may initially be in the form of a flowable liquid solution that can be mixed with the adipose matrix particles to form a slurry. The formed slurry can then be loaded into a syringe or other injection device for administration to a patient.
  • the flowable carrier may be a non-crosslinked HA in an amount sufficient to provide improved injectability of the adipose tissue product composition.
  • the flowable carrier may be a cross-linked HA in an amount sufficient to provide improved injectability of the adipose tissue product composition. While the flowable carrier is described herein as comprising HA, it is contemplated that other
  • glycosaminoglycans may be utilized as the flowable carrier, such as
  • HSGAG, CSGAG, and/or keratin sulfate type GAGs While direct surgical implantation through an open incision is a suitable option for implanting adipose tissue matrix materials to repair certain areas of the body, including a soft tissue defect following removal of an implantable injection port or other soft tissue mass, injection may be preferred for some applications. Particulating the adipose tissue matrix was found to be an
  • tissue product compositions including adipose tissue matrix particles mixed within a flowable carrier comprising a hyaluronic acid based material.
  • the formed tissue product composition can be more easily applied than pure adipose tissue matrix particles, as will be described further herein, while maintaining characteristics that encourage tissue growth in the implantation and/or injection area.
  • the adipose tissue matrix particles and flowable carrier may be mixed in a large volume batch under generally sterile conditions to form a tissue product composition in accordance with the present invention.
  • the mixing may comprise, for example, stirring the adipose tissue matrix particles and flowable carrier together to form a slurry.
  • the parameters and technique of the mixing may be altered according to the properties of the flowable carrier and the acellular tissue matrix particles, as well as the general amounts of each in the tissue product composition, and can be readily derived by one skilled in the art from routine experimentation.
  • HA Type 1 is a non-crosslinked hyaluronic acid having a G’ value of 320 Pa; HA Type 2 and HA Type 3, in contrast, are hyaluronic acids that were cross- linked with an EDC cross-linking agent with different G’ and G” values, depending on the degree of cross-linking.
  • HA Type 2 had a G’ value of 160 Pa and HA Type 3 had a G’ value of between 500-550.
  • HA Type 4 is also cross-linked. HA Type 4 may have a G’ value of 350 Pa.
  • hyaluronic acid based materials may be mixed with adipose tissue matrix particles to produce various tissue product compositions described in Table 1 below. It should be appreciated that the hyaluronic acid based materials described herein are exemplary only, and other hyaluronic acid based materials may be mixed with the adipose tissue matrix particles. Further, the compositions given in Table 1 are exemplary only, and other formulations of tissue product compositions may be formed in accordance with the present invention.
  • Compositions 1 -4 representing various tissue product compositions are illustrated in Table 1 , but it should be appreciated that other tissue product compositions may be formed in accordance with the present invention.
  • the adipose tissue matrix particles originated from porcine fat tissue and, when combined with the flowable carrier, produced adipose tissue matrix slurries, which may also be referred to as“flowable adipose tissue matrix.”
  • the flowable carrier Prior to mixing with the flowable carrier, which was provided in a concentration of 20 mg HA/mL, the adipose tissue matrix particles were in a concentration of 100 mg/mL in an aqueous buffer.
  • a ratio of Adipose Matrix: HA can be adjusted to produce slurries with varying flow properties, as will be described further herein. It should be understood that the ratios described herein can be either by volume or by mass; in the exemplary embodiments shown in Table 1 , the ratio is given as volume Adipose Matrix : volume HA. As exemplified by Compositions 1 and 2, the ratio of Adipose Matrix : HA can be 9:1 ; and as exemplified by Compositions 3 and 4, the ratio of Adipose Matrix : HA can be 4:1. It should be appreciated that the previously described ratios are exemplary only, and other exemplary embodiments of tissue product compositions may have other ratios of Adipose Matrix : HA including any values between the disclosed ratios.
  • a tissue product composition with a desired tissue matrix particle solid content may be used .
  • a material that is 5% to 15% solid content, such as 7.5% to 10% solid content may be desired depending on what type of hyaluronic acid based material is mixed with the tissue matrix particles.
  • the tissue product composition has 10% solid content, corresponding to 100 mg/mL, of acellular adipose matrix particles.
  • the tissue products should have the ability to support cell ingrowth and tissue regeneration when implanted in or on a patient.
  • the tissue products should have the ability to act as a carrier for and support the growth of cells, including stem cells, such as adipose-derived stem cells. Accordingly, the processes discussed above should not alter the extracellular matrix proteins in an unacceptable way (e.g., by damaging protein structure and/or removing important glycosaminoglycans and/or growth factors).
  • stem cells such as adipose-derived stem cells.
  • the products will have normal collagen banding as evidenced by high- resolution microscopy, such as transmission electron microscopy or atomic force microscopy, for example.
  • the tissue products are treated with a process that retains either or both of the native hyaluronic acid and chondroitin sulfate.
  • the tissue products may include either or both of hyaluronic acid and chondroitin sulfate.
  • the process may be selected to maintain native growth factors.
  • the tissue products may be produced such that the tissue products contain one or more growth factors selected from PECAM-1 ,
  • HGF HGF, VEGF, PDGF-BB, follistatin, IL-8, and FGF-basic.
  • Adipose tissue matrix may be rich in Type IV and Type VI collagens.
  • the ratio between these two types of collagens relative to Type I collagen may be different from a dermal matrix, which may be important factors used to discern adipose matrix from a dermal one, in vivo.
  • tissue products described herein may be used to treat a variety of different anatomic sites.
  • tissue products of the present disclosure are produced from adipose tissue matrices.
  • the adipose tissue products will provide superior regenerative capabilities when implanted in certain tissue sites, as compared to materials produced from other tissue types.
  • the tissue products may be implanted in tissue sites that are predominantly or significantly adipose tissue.
  • the tissue products may be used as facial fillers, e.g., to treat lines, wrinkles, voids, or divots, to add volume, or replace lost tissues.
  • the tissue sites may include a breast (e.g., for augmentation, replacement of resected tissue, or placement around an implant).
  • any other adipose-tissue containing site may be selected.
  • the tissue products may be used for reconstructive or cosmetic use in the face, buttocks, abdomen, hips, thighs, or any other site where additional adipose tissue having structure and feel similar to native adipose may be desired. In any of those sites, the tissue may be used to reduce or eliminate wrinkles, sagging, or undesired shapes.
  • the tissue may provide advantages over other tissue products. For example, although some tissue products allow ingrowth and tissue formation, those products may form significant fibrotic tissue that does not mimic normal breast texture and feel, and appears abnormal on radiologic imaging. Since the tissue products of the present disclosure are formed from adipose, they may support more normal regeneration of adipose tissue.
  • the tissue products may be used as carriers for cells.
  • the products may be implanted in any of the sites or used as discussed above, but may also be seeded with cells.
  • the cells may include stem cells such as adipose-derived stem cells.
  • other pluripotent cells may be use, as well as cells from any tissue source (e.g., blood, bone marrow, fetal stem cells, cord blood cells, etc.)
  • the cells may be seeded onto the tissue after implantation or before implantation.
  • the cells may be cultured on the tissue product before implantation and then be implanted in or on a body.
  • the particulate tissue matrix product can further comprise a flowable carrier to facilitate the injection of the tissue products.
  • the particulate tissue matrix and the flowable carrier are packaged in separate containers and are not in contact until being mixed immediately prior to injection.
  • the particulate tissue matrix and the flowable carrier are packaged in separate barrels of a multi-barrel syringe and are mixed shortly before or when the contents are being injected.
  • the particulate tissue matrix and the flowable carrier are pre-mixed and packaged together.
  • the materials may be separately dried or stored in biocompatible buffers that preserve the biologic properties of the tissue matrix and/or carrier, prevent bacterial growth, or prevent damage during sterilization or storage.
  • composition as used in the methods described below may include any of the flowable compositions comprising an adipose-derived tissue matrix product described herein above.
  • the adipose-based tissue matrix is in the form of a suspension of tissue particles having a longest dimension no greater than about 3.0 mm. In some embodiments, the adipose-based tissue matrix is in the form of a suspension of tissue particles having a longest dimension of at least 0.05 mm. In some embodiments, the adipose-based tissue matrix is in the form of a suspension of tissue particles having a longest dimension between about 100 pm and about 300 pm. In some embodiments, the adipose-based tissue matrix is in the form of a suspension of tissue particles having a longest dimension between about 50 pm and about 100 pm.
  • the composition comprises a carrier preventing dissipation of or otherwise migration of the adipose-based tissue matrix away from the void.
  • the composition further comprises a glycosaminoglycan.
  • the glycosaminoglycan is a hyaluronic acid.
  • the hyaluronic acid is a crosslinked hyaluronic acid.
  • the hyaluronic acid is a non-crosslinked hyaluronic acid.
  • the hyaluronic acid is present in the composition at a
  • the composition comprises a local anesthetic.
  • FIG. 18 is a flowchart outlining a process for creating and repairing a soft tissue void using a flowable adipose-based tissue matrix.
  • FIG. 18 shows a method 300 for treating a void in a soft tissue.
  • Method 300 comprises a removing step 310, a delivering step 320, and a closing step in some embodiments.
  • Removing step 310 comprises removing an implanted infusion port or other implanted device from an anatomic location of a subject to create a void through a skin incision.
  • the anatomic location is most commonly on the anterior chest wall over the upper (superior) aspect of the pectoralis major muscle. Less commonly, the anatomic location is on the lateral chest wall, the anterior shoulder area, the supraclavicular fossa, the lateral neck, the anterior thigh, and the anterior lower abdomen. These anatomic locations are described by way of example. The actual anatomic location will depend on the site of the implantable port and is not meant to be limiting.
  • removing the infusion port involves making a skin incision to expose the implanted port, which is usually immediately below the skin and partially encapsulated in a thin, fibrous capsule.
  • One or more sutures securing the port to the underlying fascia or muscle are cut and also removed.
  • the intravenous catheter is pulled out as one unit with the port.
  • pressure is held through the wound against the inferior aspect of the clavicle to ensure hemostasis at the catheter exit site of the vein for several minutes.
  • removing step 310 also comprises excision of any fibrous capsule that may be present. Hemostasis is achieved to prevent post removal hematoma formation.
  • Delivering step 320 is performed following removing step 310.
  • delivering step 320 comprises delivering a flowable composition comprising an adipose-based tissue matrix into the void at a time proximate to the removing step.
  • a flowable composition allows particles of the adipose-based tissue matrix to be distributed throughout all areas of the void created by removal of the implantable port, regardless of the shape of the void. Being fluid-like, the flowable composition will take the shape of the surrounding void.
  • the delivery step may be performed during the removal procedure or at a later time.
  • the delivery can be performed before closure of the skin incision.
  • the delivery can be performed at a later time if a defect such as a depression forms. In the latter case, delivery may be percutaneous or by producing a new incision.
  • the flowable composition may be delivered in a variety of ways, in some embodiments.
  • a syringe fitted with a needle is used to dispense the composition from the syringe through the needed into the void.
  • the needle may be a 14 gauge (“G”), a 16 G, an 18 G, or a 20 G needle, for example.
  • the needle is fitted with a cannula, such as an intravenous infusion cannula.
  • the cannula has a larger bore than a 14 G cannula.
  • the cannula is a 14 G cannula, a 16 G cannula, an 18 G cannula, a 20 G cannula, or a 21 G cannula.
  • the cannula has a smaller bore than a 21 G cannula.
  • a syringe without a needle is used to dispense the composition comprising the adipose-based tissue matrix into the void.
  • the syringe is fitted with a tube or tube-like device configures to dispense a flowable material.
  • an instrument other than a syringe is used to position the composition by manual insertion into the void, such as a spatula, a spoon, or the like.
  • the spatula, spoon, or similar instrument is used to place the composition into the void and push the composition, which has a putty-like consistency, in some embodiments, into the depths and side recesses of the cavity, filling the void and eliminating any residual dead space in the soft tissue.
  • a hand is used to deliver the composition by manual insertion.
  • the volume of the composition comprising a flowable acellular adipose tissue matrix should completely fill the void, in order to prevent leaving a dead space. It is also important to prevent any visible deformity of the overlying skin that results from inadequate subcutaneous volume and support.
  • the composition comprising a flowable acellular adipose tissue matrix generally loses a small percentage of its volume as the acellular adipose tissue matrix is incorporated into the subject’s soft tissue.
  • method steps include delivery of a volume of the flowable adipose tissue matrix generally equal to or slightly greater than the volume of the removed implantable port, or other removed soft tissue mass.
  • the delivered volume of the flowable adipose tissue matrix is about 95% to about 100% of the volume of the removed mass. In some embodiments, the delivered volume of the flowable adipose tissue matrix is about 100% to about 105% of the volume of the removed mass. In some embodiments, the delivered volume of the flowable adipose tissue matrix is about
  • Closing step 330 comprises closing the incision.
  • Closing step 330 may be performed, by example, by using an available closing means known in the art, including but not limited to suturing or stapling the skin edges together.
  • Dermal adhesives designed for skin closures such as those containing cyanoacrylate and other poly-acrylate compounds used as medical adhesives, may also or alternatively be used. Regardless of the specific means used to close the skin incision, it is important to achieve a fluid-tight closure, both to facilitate aesthetic healing of the incision and to prevent the adipose-based tissue matrix material from leaking form the void through the improperly closed skin incision.
  • closing step 330 is performed to close the incision and“seal” the wound.
  • the unsupported skin overlying the void created during removing step 310 will be seen to“sag.”
  • Delivering step 320 is then performed by injecting the flowable composition through a needle inserted percutaneously until the skin overlying the void is fully supported, preferably with a slight excess rise above the surrounding skin to allow for volume loss as the adipose-based tissue matrix becomes
  • FIG. 19 is a flowchart outlining a process for repairing a skin deformity using a flowable adipose-based tissue matrix.
  • FIG. 19 shows a method 400 comprising an incising step 410, a dividing step 420; an injecting step 430; and a closing step 440.
  • Incising step 410 comprises incising the skin proximate to a deformity.
  • a site for the skin incision is chosen according to the location, size, and severity of the defect. Often, it may be desirable to make the incision through non-deformed skin adjacent to the deformity.
  • the skin incision may be a small 2-4 mm“stab” incision just large enough to accommodate a small pair of fine scissors or other instrument into the subcutaneous space. In some cases, it may be necessary to lengthen the incision.
  • the incision is made through the deformed skin. The procedure is typically done under local anesthesia, which is injected into the skin at the planned incision site, and into the subcutaneous tissue underlying the skin deformity. Use of a local anesthetic composition
  • Dividing step 420 comprises dividing subcutaneous scar tissue to release skin attached to the scare tissue, creating a dead space.
  • a suitable instrument such as a small pair of fine dissecting scissors or a long-handled scalpel is passed through the skin incision and used to cut through bands of scar tissue tethering the overlying skin, thereby releasing the scar tissue attachments to the overlying skin.
  • hemostasis can usually be obtained by direct pressure on the skin for a few minutes. If this is not effective, the incision may be lengthened and electrocautery or other means is used to secure hemostasis.
  • Injecting step 430 comprises injecting a flowable composition containing an adipose-based tissue matrix into the dead space created by dividing step 420.
  • Injecting step 430 is performed in a similar matter using similar devices as in delivering step 320 described herein above.
  • a syringe is preferably used, however, because the incision is small and a slow, controlled delivery of the composition comprising the adipose-based tissue matrix allows the surgeon to watch the released skin become supported as the volume of injected composition increases. The surgeon can then decide, based on an anticipated volume loss of around fifteen percent (15%) as the adipose-based tissue matrix becomes incorporated into and largely replaced by the patients subcutaneous fat tissue over time.
  • Closing step 440 comprises closing the skin incision.
  • the small stab incision made during incision step 410 can be closed with a single subcuticular (“deep”) absorbable stitch.
  • closing step 440 is performed similarly to closing step 330 described herein above.
  • closing step 330 is performed to close the incision and“seal” the wound.
  • the unsupported skin at the site of the deformity will be seen to“sag.”
  • Injecting step 430 is then performed by injecting the flowable composition through a needle inserted percutaneously until the skin is fully supported, preferably with a slight excess rise above the surrounding skin to allow for volume loss as the adipose-based tissue matrix becomes incorporated in the patient’s subcutaneous adipose tissue.
  • porcine fat tissue was first sliced into 2-inch strips and coarsely chopped in a food grade meat chopper.
  • the chopped fat tissue may be frozen at -80° C, if not ready for further process.
  • the frozen material may be thawed either at room temperature or 4° C overnight.
  • the preprocessed material was further coarse ground with RETSCH® GM300
  • the adipose matrix solid was harvested by centrifugation and washed with buffer.
  • the matrix material was decellularized with an EDTA-Triton solution at room temperature overnight with one solution change at four hours.
  • the matrix protein was subjected to washes again. During washing, the matrix pellet is centrifuged to pellet the tissue matrix and decant the used solution. The suspension was mechanically grinded again to further break down matrix fibers. After washing, the matrix pellet was resuspended in 20% PBS at a solid
  • the slurry was placed in a metal tray and was freeze dried to form a sponge and subject to DHT treatment to stabilize the material.
  • the stabilized sponge was then ground and sieved to obtain a desired size of particles as flowable/injectable porcine acellular tissue slurry (PATS) material.
  • PATS flowable/injectable porcine acellular tissue slurry
  • tissue product produced with the process described above was subjected to analysis with a Scanning Electron Microscope (SEM) and an Atomic Force Microscope (AFM).
  • SEM Scanning Electron Microscope
  • AFM Atomic Force Microscope
  • the results showed that the tissue product is a porous scaffold containing collagen materials with typical collagen banding pattern, including structure, porosity, etc., as shown in FIG. 6.
  • the microscopy indicates intact collagen with normal banding patterns.
  • the DSC results indicate that the tissue product has an onset melting temperature at 61.5° C.
  • the tissue product ’s onset melting temperature was similar to native tissue (e.g., raw adipose).
  • FIG. 7C depicts collagenase digestion curves for adipose tissue produced according to the disclosed Example - with and without e-beam sterilization. Without e-beam sterilization, and only DFIT stabilization, the percentage of solid remaining as function of hours of digestion drops to approximately 18% after eight hours. With e-beam sterilization together with DFIT stabilization, the
  • ⁇ &E hematoxylin and eosin staining
  • the tissue was subject to immune-histological analysis for major extracellular matrix proteins including Type I, Type III and Type IV.
  • major extracellular matrix proteins including Type I, Type III and Type IV.
  • the adipose tissue product lower row
  • preserved original characteristics of native adipose matrix upper row
  • tissue product sponge has potential to support the growth of adipose tissue, vasculature, and other connective tissue like dermal tissue.
  • adipogenic mesenchymal stem cells, endothelial cells, and dermal fibroblasts all primary cells isolated from normal humans individuals.
  • the tissue product was seeded with cells isolated from these tissues and cultured for 1 , 7, and 16 days.
  • the cell growth was quantified with a cell proliferation assay kit.
  • CyQUANT® Cell Proliferation Assay Kit the cell proliferation was quantified by DNA content using fluorescent dye.
  • the tissue product was analyzed for cell growth.
  • the cell seeded scaffold was stained with live-dead staining solution and the viability and growth of cells were observed under fluorescent light microscopy.
  • the tissue product supports all three types of cell growth in vitro. F. Tissue Product Retained Volume and Supported Adipogenesis In Vivo:
  • Arm 1 The product fabricated as described in Example A was grouped into five different size ranges: Arm 1 : 2.8-3.4 mm; Arm 2: 0.8-1.0 mm; Arm 3: 0.4-0.6 mm; Arm 4: 0.05-0.1 mm; and Arm 5, 0.1 -1 mm.
  • Arm 6 included a slurry and fiber in nature that was the material obtained directly from after the decellularization process, without freeze drying and subsequent steps. Arm 6 was used as a control for comparison to the tissue product with DHT stabilized 3D microporous structures as in Arms 1 -5.
  • Arm 7 included a sponge prepared by a similar process, but from dermal acellular tissue matrix. The dermal tissue was Strattice®.
  • Arms 1-5 were first hydrated at 10% solid content by weight in normal saline to make injectable pastes, and Arm 6 was also similarly adjusted to 10% solid content.
  • Arm 7 was a 10 mm punch in 5 mm thickness from a dermal sponge and hydrated in PBS. About 0.5 cc aliquot of each injectable adipose material (Arms 1 -6), and the 10 mm punch of Arm 7, were implanted at the subcutaneous region of nude rats for triplicates of each arm.
  • FIG. 11 illustrates gross observation of explants of injectable adipose tissue matrix after subcutaneous implant in nude rats. A dotted line indicates implanted material. All the explants were soft when palpated. Injectable adipose with all particle size ranges persisted for at least 4 weeks. It was also observed (data not shown) that injectable adipose implants with certain particle sizes persisted well for at least 12 weeks.
  • FIG. 12 illustrates additional Masson’s trichrome staining of the explants at lower magnification.
  • a robust adipogenic response with tissue in-growth was observed for Arms 1 -4 that were prepared from stabilized PATS sponges.
  • the adipose tissue matrix slurry of Arm 6 lacking any 3D structure (i.e. , absence of freeze-drying and stabilization), elicited no adipogenic response (c).
  • Arm 7 as shown in FIG. 12, further illustrates an intact sponge-like porcine dermal tissue scaffold when implanted in the sub cutaneous space of the same nude rat model. Masson’s trichrome staining reveals no adipose tissue regeneration in the dermal scaffold, although volume was retained.
  • FIGs. 14A-14C are zoomed-in Masson’s Trichrome stained sections of explants from Arm 2, showing good adipogenesis. Adipocytes are white areas, which were plentiful and large; and vascularization was evident. Similar histologic findings were present with Arm 5 samples (not illustrated in the Figures).
  • Fig. 15 provides images of fresh adipose tissue matrix, as compared to tissue matrix stored for 1.5 years, both of which were prepared as described in Example A. The images are provided at various magnifications. As illustrated, an adipose tissue matrix material in a wet format containing 10% solid formed aggregates after 1.5 years of storage. Biologic tests indicate that the aggregation does not impact biological performance of the material such as volume retention and adipose tissue in-growth in the subcutaneous region of nude rat.
  • the 10% adipose tissue product may require a carrier to facilitate Injectability.
  • a 20 mg/mL, non-crosslinked hyaluronic acid (HA) carrier was mixed with either a freshly prepared adipose tissue matrix (10%, 0.1 -1.0 mm) or a 1.5-year-old adipose tissue matrix (10%, 0.1 -1 mm).
  • the final concentration of the HA additive in the mixed material was 2 mg/mL.
  • the compressive load (N) required for injection of the adipose material, with or without the HA additive was evaluated on an Instron Model 5865 materials tester (Instron Corporation, Norwood, MA).
  • the adipose material without HA was injected through either a 16 G needle or an 18 G needle, and the adipose material with HA additive was injected through an 18 G needle.
  • a 1 : 10 ratio of 20 mg/mL, cross-linked hyaluronic acid (HA Type 4) and the adipose tissue matrix (10%) were mixed, and the mixture was injected into the subcutaneous region of a nude rat.
  • An explant of the HA-adipose product mixture was harvested 4 weeks after the injection and as depicted in Fig. 17, a robust adipose tissue ingrowth was observed in the explant.
  • FIG. 20 is a graph illustrating volume retention of an adipose matrix composition implanted subcutaneously for up to twelve weeks, according to the disclosed Examples. As shown, the adipose matrix maintains up to 90% volume even at twelve weeks.
  • Example I Acute and Chronic Wound Model Improvement Using Adipose Tissue Matrix
  • CDW Chronic Defect Wound
  • ADW Acute Defect Wound
  • CDW model after the wound defects were created on Day -4, the wounds further received thermal injury to delay an acute wound healing process.
  • the wound defects were surgically debrided and then treated with or without 10% adipose matrix product.
  • the adipose product was prepared as described in Example A with particles in the range of 1 - 3mm.
  • the adipose matrix For ADW model, the wound defects were created on Day 0 and were immediately treated with or without 10% adipose matrix product. Animals for each model were terminated 14- and 28-days post implantation.
  • each entire wound was excised with at least 2 cm of surrounding tissue attached. Gross observation of each wound and surrounding tissue was performed to evaluate wound healing with different treatments in CDW or ADW models, followed by histology evaluation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des compositions et des procédés de traitement de tissus. Les compositions peuvent comprendre une matrice de tissulaire dérivée de tissus adipeux, appropriée pour une injection, une implantation de petit volume ou une utilisation en tant que matériau de régénération de tissus mous. L'invention concerne également des procédés de production de telles compositions.
PCT/US2020/040582 2019-07-03 2020-07-02 Procédés de traitement de vides tissulaires après élimination de ports de perfusion implantables à l'aide de produits de tissus adipeux Ceased WO2021003321A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/502,640 US11123375B2 (en) 2017-10-18 2019-07-03 Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
US16/502,640 2019-07-03

Publications (1)

Publication Number Publication Date
WO2021003321A1 true WO2021003321A1 (fr) 2021-01-07

Family

ID=71784681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/040582 Ceased WO2021003321A1 (fr) 2019-07-03 2020-07-02 Procédés de traitement de vides tissulaires après élimination de ports de perfusion implantables à l'aide de produits de tissus adipeux

Country Status (1)

Country Link
WO (1) WO2021003321A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190111183A1 (en) * 2017-10-18 2019-04-18 Lifecell Corporation Adipose tissue products and methods of production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190111183A1 (en) * 2017-10-18 2019-04-18 Lifecell Corporation Adipose tissue products and methods of production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, HUI ET AL.: "A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-a-(1,3)-Galactose and Retention of Matrix Structure", TISSUE ENGINEERING, vol. 15, 2009, pages 1 - 13, XP002528175, DOI: 10.1089/ten.tea.2008.0384

Similar Documents

Publication Publication Date Title
US11123375B2 (en) Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
US20250065018A1 (en) Adipose tissue products and methods of production
US12311079B2 (en) Decellularized biomaterial from non-mammalian tissue
US10722339B2 (en) Flowable tissue products
JP5963208B2 (ja) 再生組織足場
US20230211048A1 (en) Biologic breast implant
WO2020172602A1 (fr) Matrices musculaires décellularisées et leurs procédés de fabrication et d'utilisation
WO2021003321A1 (fr) Procédés de traitement de vides tissulaires après élimination de ports de perfusion implantables à l'aide de produits de tissus adipeux
JP7785886B2 (ja) 脂肪組織製品および製造方法
CN113633825A (zh) 一种负载bFGF的肝素化脱细胞脂肪材料的制备方法及应用
WO2021202965A1 (fr) Matrice de tissu adipeux avec tropoélastine
HK1173180A (en) Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20745400

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20745400

Country of ref document: EP

Kind code of ref document: A1